Company’s novel platform enables clinically relevant molecular profiling of circulating tumor cells isolated from the bloodstream
Westlake Village, Calif., November 25, 2013 -- Cynvenio, a cancer diagnostics company focused on transforming cancer treatment through the genomic analysis of tumor cells in the bloodstream, today announced that the company’s automated LiquidBiopsy platform has been independently evaluated and selected by Frost & Sullivan as the winner of their 2013 Technology Innovation Leadership Award.
Frost & Sullivan used a ten-step process to benchmark Cynvenio’s technology for:
- Uniqueness of the Technology
- Impact on New products/applications
- Impact on Functionality
- Impact of Customer Value
- Relevance of Innovation to Industry
Frost & Sullivan concluded that “Cynvenio’s LiquidBiopsy platform has established itself as the best systematic approach in capturing CTCs to the degree of 99.99% purity required for conducting any downstream molecular analysis. Not only does Cynvenio provide the number of CTCs that are present in the blood sample, but this solution also delivers full-fledged analysis with details on the mutations that are present. Cynvenio provides a cost-effective tool that can be used by physicians to aid them in the process of developing a treatment plan for their cancer patients. While Cynvenio’s LiquidBiopsy platform currently has the capacity to provide results that are close to the ones obtained by a real-tissue biopsy, it is also a more feasible approach that can be used to analyze and observe the long-term effects of a patient’s cancer progression. Cynvenio has opened new avenues in the oncology and personalized medicine fields and truly deserves the 2013 Frost & Sullivan Technology Innovation Leadership Award.”
“We are thrilled to have won the 2013 Technology Leadership Award” commented André de Fusco, Cynvenio’s CEO. “Our team has demonstrated over thousands of clinical samples that our LiquidBiopsy platform consistently delivers the higher purity needed for molecular analysis, including next generation sequencing. This capability, rather than legacy approaches such as CTC enumeration, is the key to enabling physicians to build evidence-based, individualized treatment plans that can improve patient outcomes.”
About Cynvenio Biosystems, Inc.
Cynvenio is a cancer diagnostics company focused on transforming cancer treatment through the molecular analysis of tumor biomarkers in the bloodstream. This expertise has resulted in two distinct product offerings: ClearID Breast Cancer molecular testing program and LiquidBiopsy. ClearID Breast Cancer assesses 50 oncogenes for more than 4,500 genetic mutations using next-generation sequencing. This test and real-time molecular analysis provide actionable information that can inform treatment considerations and help improve treatment outcomes. LiquidBiopsy is designed for industry and academic researchers to identify the presence of tumor-cell genetic mutations in whole blood. Founded in 2008, Cynvenio is headquartered in Westlake Village, Calif. (Los Angeles). For more information visit http://www.cynvenio.com.
LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.
About Frost & Sullivan’s Best Practices Awards
Frost & Sullivan Best Practices Awards identify exemplary achievements within a multitude of industries and functional disciplines. The analysis on best practices that we conduct identifies companies, products, processes, and executives that have achieved world-class performances. This research is an invaluable source to companies for new ideas to improve strategies and processes, which ultimately drive corporate growth. These achievements are recognized with Frost & Sullivan Best Practices Awards. The LiquiBiopsy report is available here.